Biotech Acquisition Company Unit
BIOTU
BIOTU was delisted on the 2nd of February, 2023.
41 hedge funds and large institutions have $60.1M invested in Biotech Acquisition Company Unit in 2021 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 22 closing their positions.
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
31% less funds holding
Funds holding: 59 → 41 (-18)
49% less capital invested
Capital invested by funds: $118M → $60.1M (-$58.2M)
82% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
Rivernorth Capital Management
West Palm Beach,
Florida
|
+$1.93M |
| 2 |
PMAM
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
|
+$1.5M |
| 3 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
+$538K |
| 4 |
SMA
Sage Mountain Advisors
Atlanta,
Georgia
|
+$230K |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$167K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
-$9.89M |
| 2 |
LA
Linden Advisors
New York
|
-$6.71M |
| 3 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$4.91M |
| 4 |
DCM
DG Capital Management
New York
|
-$4.45M |
| 5 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
-$4.01M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KC
51
Kepos Capital
New York
| – | -$2.62M | -264,400 | Closed |
|
|
PSAMP
52
P. Schoenfeld Asset Management (PSAM)
New York
| – | -$1.98M | -200,000 | Closed |
|
|
WAM
53
Wolverine Asset Management
Chicago,
Illinois
| – | -$1.93M | -194,844 | Closed |
|
|
SCM
54
Saba Capital Management
New York
| – | -$1.78M | -179,960 | Closed |
|
|
TI
55
Telemetry Investments
New York
| – | -$1.04M | -105,000 | Closed |
|
|
LP
56
LMR Partners
London,
United Kingdom
| – | -$989K | -100,000 | Closed |
|
57
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$598K | -60,459 | Closed |
|
58
Alyeska Investment Group
Chicago,
Illinois
| – | -$593K | -60,000 | Closed |
|
|
AA
59
AQR Arbitrage
Greenwich,
Connecticut
| – | -$524K | -53,000 | Closed |
|
|
CC
60
Centiva Capital
New York
| – | -$495K | -50,000 | Closed |
|
|
LC
61
Littlejohn & Co
Greenwich,
Connecticut
| – | -$495K | -50,000 | Closed |
|
|
OAC
62
OMERS Administration Corp
Toronto,
Ontario, Canada
| – | -$247K | -25,000 | Closed |
|
|
AA
63
Ancora Advisors
Cleveland,
Ohio
| – | -$100K | -10,100 | Closed |
|
BIOTU Hedge Fund Activity: Q2 2021 in Review
41 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Unit (BIOTU) for Q2 2021, worth a combined $60.1M — down 49% from $118M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of BIOTU and 4 opened new positions — a net loss of 18 holders — while 8 trimmed existing stakes and 7 added.
The largest buyer was Rivernorth Capital Management, adding an estimated $1.93M. The largest seller was BlueCrest Capital Management, exiting entirely with an estimated $9.89M sold.
- 41 institutional investors held Biotech Acquisition Company Unit (BIOTU) as of Q2 2021, down from 59 in Q1 2021.
- Funds reported $60.1M of Biotech Acquisition Company Unit stock for Q2 2021, down 49% quarter-over-quarter.
- 4 funds opened new Biotech Acquisition Company Unit positions in Q2 2021 and 22 closed out, a net change of -18 holders.
- The largest Biotech Acquisition Company Unit buyer in Q2 2021 was Rivernorth Capital Management, an estimated $1.93M added.
- The largest Biotech Acquisition Company Unit seller in Q2 2021 was BlueCrest Capital Management, an estimated $9.89M sold.
Based on aggregated 13F filings for Q2 2021.